Mukul Singhal
Overview
Explore the profile of Mukul Singhal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Singhal M, Valderrama A, Nepal B, Kamble S, Eluri M, et al.
Future Oncol
. 2024 Aug;
20(34):2625-2636.
PMID: 39155836
To evaluate real-world treatment patterns, survival and healthcare-resource utilization in US patients with advanced biliary tract cancers (BTC) receiving systemic therapy. This study used claims data from the Healthcare Integrated...
2.
Bakris G, Lin P, Xu C, Chen C, Ashton V, Singhal M
J Clin Hypertens (Greenwich)
. 2024 Mar;
26(5):500-513.
PMID: 38523465
Apparent treatment-resistant hypertension (aTRH), defined as blood pressure (BP) that remains uncontrolled despite unconfirmed concurrent treatment with three antihypertensives, is associated with an increased risk of developing cardiovascular and renal...
3.
Bakris G, Chen C, Campbell A, Ashton V, Haskell L, Singhal M
Am J Hypertens
. 2024 Mar;
37(6):438-446.
PMID: 38436491
Background: Chronic kidney disease (CKD) is a common comorbidity in patients with apparent treatment-resistant hypertension (aTRH). We assessed clinical outcomes, healthcare resource utilization events, and costs in patients with aTRH...
4.
Bakris G, Chen C, Campbell A, Ashton V, Haskell L, Singhal M
J Clin Hypertens (Greenwich)
. 2023 Jul;
25(8):737-747.
PMID: 37461262
Patients with apparent treatment-resistant hypertension (aTRH) are at increased risk of end-organ damage and cardiovascular events. Little is known about the effects of blood pressure (BP) control in this population....
5.
Kloner R, Stanek E, Crowe C, Singhal M, Pepe R, Bradsher J, et al.
J Sex Med
. 2023 Mar;
20(1):38-48.
PMID: 36897243
Background: Treatment with phosphodiesterase type 5 inhibitors (PDE-5is) is effective in treating erectile dysfunction (ED). Aim: The objective of this study was to determine the effect of PDE-5is on the...
6.
Tom N, Harshvardhan L, Singhal M, Agarwal M, Mathur A, Jain T
J Assoc Physicians India
. 2022 Apr;
70(4):11-12.
PMID: 35443385
Material: We recruited 35 Normotensive, Non-Diabetic Non-Alcoholic Fatty Liver Disease Patients (NAFLD) of age ranging from 18 to 60 years of age diagnosed on the basis of ultrasound Abdomen and...
7.
Singhal M, Sharma S, Tom N, Agarwal M, Mathur A
J Assoc Physicians India
. 2022 Apr;
70(4):11-12.
PMID: 35443330
Material: A prospective, analytical study was conducted from March 2021 to December 2021 encompassing 100 hemodynamically stable patients with cirrhosis without infection, admitted at SMS Medical College, Jaipur, who were...
8.
Gerds A, Yu J, Scherber R, Paranagama D, Kish J, Visaria J, et al.
Acta Haematol
. 2022 Jan;
145(4):448-453.
PMID: 35008087
Ruxolitinib is an FDA-approved treatment of intermediate- and high-risk myelofibrosis. In the phase 3 COMFORT studies, ruxolitinib reduced spleen volume in patients with myelofibrosis, with a median time to response...
9.
Stephenson J, Gable J, Zincavage R, Price G, Churchill C, Zhu E, et al.
Patient Prefer Adherence
. 2021 Nov;
15:2417-2429.
PMID: 34764640
Purpose: To describe patients' perspectives on the use of and potential challenges and barriers with adherence/persistence to cyclin-dependent kinase 4 and 6 inhibitors (CDK4&6i's) to treat metastatic breast cancer (MBC)....
10.
Singhal M, Tan H, Coleman C, Han M, Nguyen C, Ingham M
BMJ Open Diabetes Res Care
. 2019 Dec;
7(1):e000704.
PMID: 31798890
Introduction: This real-world study compared glycemic effectiveness, treatment durability, and treatment costs with canagliflozin 300 mg versus any dose of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2...